Loading...
•
Dec 31, 2024
Beam Therapeutics Q4 2024 Earnings Report
Reported fourth quarter and year-end financial results and reiterated anticipated catalysts.
Key Takeaways
Beam Therapeutics reported a net loss of $90.4 million for Q4 2024, with cash, cash equivalents, and marketable securities totaling $850.7 million. The company achieved its adult enrollment target in the BEACON trial and anticipates key milestones for its BEAM-101, ESCAPE, BEAM-301, and BEAM-302 programs.
Achieved adult enrollment target for BEACON Phase 1/2 clinical trial of BEAM-101 for sickle cell disease.
Presented initial results for the BEACON trial at the 66th American Society of Hematology (ASH) Annual Meeting.
Advanced global regulatory and site activation activities for BEAM-302 for alpha-1 antitrypsin deficiency (AATD).
Activated the first clinical trial site for the Phase 1/2 clinical trial of BEAM-301 for glycogen storage disease type 1a (GSD1a).
Beam Therapeutics
Beam Therapeutics
Forward Guidance
Beam Therapeutics anticipates several milestones in 2025, including updated data from the BEACON trial, initial data from the BEAM-302 trial, and the commencement of patient dosing in the BEAM-301 trial.
Positive Outlook
- Expects to present updated data in mid-2025 from the BEACON Phase 1/2 clinical trial of BEAM-101 in adults with severe SCD.
- Expects to dose 30 patients in the BEACON trial by mid-2025.
- Expects to initiate a Phase 1 healthy volunteer clinical trial of BEAM-103, the ESCAPE monoclonal antibody, by the end of 2025.
- Expects to report initial data from multiple cohorts from the Phase 1/2 study of BEAM-302 in AATD in the first half of 2025.
- Patient dosing in the Phase 1/2 clinical trial of BEAM-301 in GSD1a is expected to commence in early 2025.